Antifungal antibiotics

Applied Microbiology and Biotechnology

Volumn 58, Issue 1, 2002, Pages 46-57

  Gupte, Monali ^a   Kulkarni, P ^a   Ganguli, B N ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYLAMINE DERIVATIVE; AMOROLFINE; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BAFILOMYCIN; BENANOMICIN A; CORYNECANDIN; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; GRISEOFULVIN; KETOCONAZOLE; MICONAZOLE; MORPHOLINE DERIVATIVE; NAFTIFINE; NIKKOMYCIN; NUCLEOSIDE DERIVATIVE; NYSTATIN; PAPULACANDIN DERIVATIVE; PENTAMIDINE; POLYENE ANTIBIOTIC AGENT; PYRROLE DERIVATIVE; TERBINAFINE; THIOCARBAMIC ACID DERIVATIVE; TOLNAFTATE; UNCLASSIFIED DRUG;

ANTIBIOTICS; FUNGAL DISEASE;

AMINO ACID SYNTHESIS; ANTIBIOTIC RESISTANCE; CANDIDIASIS; DERMATOMYCOSIS; DRUG EFFICACY; DRUG MECHANISM; ELECTRON TRANSPORT; INFECTION CONTROL; MYCOSIS; NONHUMAN; SHORT SURVEY;

ANTIBIOTICS, ANTIFUNGAL; FUNGI; HISTORY, 20TH CENTURY; HUMANS; MYCOSES;

EID: 0036169246     PISSN: 01757598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002530100822     Document Type: Short Survey

References (106)

1. Antifungal resistance trends towards the year 2000: Implications for therapy and new approaches
2. Procedure for testing antibiotics in agar media: Theoretical considerations
3. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
4. Secular trends in the epidemiology of nosocomial fungal infections in the United States 1980-1990
5. Antimicrobial agents: Antifungal agents
6. Multi drug resistance in Candida albicans
7. Identifying small-molecule lead compounds: The screening approach to drug discovery
8. A substance causing abnormal development of fungal hyphae produced by Penicillium janczewskii Zal
9. Fungal cell-wall synthesis: The construction of a biological structure
10. Adherence and receptor relationships of Candida albicans
11. Anti-Candida activity of cispentacin: The active transport by amino acid permeases and possible mechanisms of action
12. Phospholipid biosynthesis in yeast
13. The preparation of zaragozic acid analogues by directed biosynthesis
14. Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: Possible role for drug efflux in drug resistance
15. Candida albicans and three other Candida species contain an elongation factor structurally and functionally analogous to elongation factor 3
16. Natural products in drug discovery and development
17. Antifungal agents - Past, present and future possibilities
18. Metabolic products of microorganisms 255. Nikkomycins Wz and Wx, new chitin synthetase inhibitors from Streptomyces tendae
19. Structure-activity relationships of the nikkomycins
20. Emerging novel antifungal agents
21. Identification of the aminocatechol A-3253 as an in-vitro poison of DNA topoisomerase I from Candida albicans
22. Characterization of DNA Topoisomerase I from Candida albicans as a target for drug discovery
23. Haliangicin, a novel antifungal metabolite produced by a marine myxobacterium 1. Fermentation and biological characteristics
24. Haliangicin, a novel antifungal metabolite produced by a marine myxobacterium 2. Isolation and structural elucidation
25. Azoxybacilin, a novel antifungal agent produced by Bacillus cereus NR2991, production, isolation and structure elucidation
26. The fungal cell wall as a drug target
27. Human mycoses: Drugs and targets for emerging pathogens
28. Antifungal agents: Chemotherapeutic targets and immunologic strategies
29. 1α: Fermentation, isolation, biological properties
30. The polyenes: Properties, biosynthesis and fermentation
31. Identity of griseofulvin and "curling factor"
32. Comparison of in vitro antifungal susceptibilities of conidia and hyphae of filamentous fungi
33. Griseofulvin inhibits fungal mitosis
34. Corynecandin: A novel antifungal glycolipid from Coryneum modonium
35. Two antifungal agents produced by soil actinomycetes
36. 2) antagonists: Fermentation, isolation, physico-chemical properties, and biological activity
37. Calcineurin: Structure, function and inhibition
38. Induction of extracellular proteinase in Candida albicans
39. Sphingofungins E and F: Novel serine palmitoyltransferase inhibitors from Paecilomyces variotii
40. WF11899A, B and C, novel antifungal lipopeptides I. Taxonomy, fermentation, isolation and physico-chemical properties
41. WF11899A, B and C, novel antifungal lipopeptides II. Biological properties
42. Antimitotic agents: Chemistry and recognition of tubulin molecule
43. Antifungal agents - Past, present and future possibilities
44. Potential therapeutic applications of magainins and other antimicrobial agents of animal origin
45. Novel pentamidine analogues in the treatment of experimental Pneumocystis carinii pneumonia
46. Analysis of pneumocystis fatty acids
47. Doorigocins: Novel antifungal antibiotics that change the morphology of ras-transformed NIH/3T3 cells to that of normal cells. I. Taxonomy of the producing organism, fermentation and biological activity
48. Trends in antifungals: Past, present and future
49. Isolation and characterization of an antifungal antibiotic (GR 135402) with protein synthesis inhibition
50. Antifungal agents: Recent developments
51. Isolation and structures of an antifungal antibiotic, fusarielin A and related compounds produced by Fusarium sp.
52. Cispentacin, a new antifungal antibiotic I. Production, isolation, physicochemical properties and structure
53. The structure and chemistry of actidione, an antibiotic from Streptomyces griseus
54. New antifungal drug targets: A vision for the future
55. Lipopeptide inhibitors of fungal glucan synthase
56. Challenges in antibacterial and antifungal drug discovery
57. Actidione, an antibiotic from Streptomyces griseus
58. Tricholin, a new antifungal agent from Trichoderma viride, and its action in biological control of Rhizoctonia solani
59. Isolation of novel inhibitors of sphingolipids synthesis: Australifungin, viridiofungins, rustimicin and khafrefungin
60. Viridiofungins, novel inhibitors of sphingolipid synthesis
61. Biosynthesis of polyene macrolide antibiotics
62. Antifungal drugs: Mechanisms of action, drug resistance, susceptibility testing and assays of activity in biological fluids
63. Inhibitors of sterols biosynthesis and their applications
64. Cloning of the Candida albicans homolog of Saccharomyces cerevisiae GSC1/FKS1 and its involvement in 1,3-β-glucan synthesis
65. Use of antibiotics in agriculture
66. Bioactive microbial products: Focus upon mechanism of action
67. Fungal plasma membrane protein pumps as promising new antifungal targets
68. o, a new antifungal agent and potent inhibitor of Pneumocystis carinii
69. Folimycin (concanamycin A), an inhibitor of V-type H+-ATPase, blocks cell surface expression of virus-envelope glycoproteins
70. Effect of granulocyte colony-stimulating factor on the candidacidal activity of polymorphonuclear neutrophils and their collaboration with fluconazole
71. Resistance of yeasts to azole-derivative antifungals
72. Rationally designed inhibitors for sterol biosynthesis
73. Studies on the biochemistry of microorganisms 60. Griseofulvin, C17H17O6C1, a metabolic product of Penicillium griseofulvum Dierckx
74. Antifungal agents to manage mycotic infections
75. The phosphoinositol sphingolipids of Saccharomyces cerevisiae are highly localised in the plasma membrane
76. The new fungal opportunists are coming
77. Extremophiles
78. Extremophilic organisms as an unexplored source of antifungal compounds
79. Sequence analysis of the translational elongation factor 3 from Saccharomyces cerevisiae
80. The secreted aspartate proteinase of Candida albicans: Physiology of secretion and virulence of a proteinase-deficient mutant
81. Mulundocandin, a new lipopeptide antibiotic I. Taxonomy, fermentation, isolation and characterization
82. Melithiazols, new β-methoxyacrylate inhibitors of the respiratory chain isolated from myxobacteria
83. Novel aspartyl proteinase inhibitors YF-0200R A and B
84. Calcium dependent anticandidal action of pradimicin A
85. Pneumocandins from Zalerion arboricola IV. Biological evaluation of natural and semisynthetic pneumocandins for activity against Pneumocystis carinii and Candida species
86. L-671,329, a new antifungal agent. I. Fermentation and isolation
87. Targeted screening for elongation factor Tu binding antibiotics
88. Preclinical evaluation of antifungal agents
89. Laboratory studies with antifungal agents: Susceptibility tests and bioassays
90. The function of chitin synthases 2 and 3 in the Saccharomyces cerevisiae cell cycle
91. YM-47522, a novel antifungal antibiotic produced by Bacillus sp. I. Taxonomy, fermentation, isolation and biological properties
92. Cloning of the chitin synthase 3 gene from Candida albicans and its expression during yeast-hyphal transition
93. YM-47522, a novel antifungal antibiotic produced by Bacillus sp. II. Structure and relative stereochemistry
94. New antibiotics, benanomicins A and B from an actinomycete
95. Schizostatin, a novel squalene synthase inhibitor produced by the mushroom, Schizophyllum commune I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities
96. Glucan biosynthesis in fungi and its inhibition
97. UK-3A, a novel antifungal antibiotic from Streptomyces sp. 517-02: Fermentation, isolation, structural elucidation and biological properties
98. Studies on the mode of antifungal action of pradimicin antibiotics. II. D-mannopyranoside binding site and calcium binding site
99. Antibiotic search and production: An overview
100. General aspects of secondary metabolism
101. Structure and function of sterols in fungi
102. The production of an antifungal antibiotic by Streptomyces griseus
103. Antifungal drug resistance in Candida albicans
104. Clinical, cellular and molecular factors that contribute to antifungal drug resistance
105. New potential targets for antifungal development
106. Characterization of a novel, potent and specific inhibitor of serine palmitoyltransferase